AR068910A1 - Preparacion farmaceutica solida de tipo matriz que comprende un polimero enterico - Google Patents

Preparacion farmaceutica solida de tipo matriz que comprende un polimero enterico

Info

Publication number
AR068910A1
AR068910A1 ARP080104534A ARP080104534A AR068910A1 AR 068910 A1 AR068910 A1 AR 068910A1 AR P080104534 A ARP080104534 A AR P080104534A AR P080104534 A ARP080104534 A AR P080104534A AR 068910 A1 AR068910 A1 AR 068910A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical preparation
enteric polymer
solid pharmaceutical
matrix type
release
Prior art date
Application number
ARP080104534A
Other languages
English (en)
Inventor
Kai Suzuki
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40567911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR068910(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR068910A1 publication Critical patent/AR068910A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una preparacion solida de tipo matriz que tiene una gran capacidad de control de la liberacion para suprimir la liberacion del fármaco en el tracto gastrointestinal superior y acelerar la liberacion del fármaco en el tracto gastrointestinal inferior, y que supera todas las desventajas causadas al combinar un plastificante. La presente brinda una preparacion farmacéutica solida de tipo matriz que contiene: (a) un polímero entérico a base de ácido metacrílico; y (b) un azucar y/o un alcohol de azucar, donde 1 g del azucar y/o alcohol de azucar se puede disolver en no más de 4 g de agua en cierto punto de la temperatura del agua que oscila entre 20 y 25°C.
ARP080104534A 2007-10-19 2008-10-17 Preparacion farmaceutica solida de tipo matriz que comprende un polimero enterico AR068910A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007272700 2007-10-19

Publications (1)

Publication Number Publication Date
AR068910A1 true AR068910A1 (es) 2009-12-16

Family

ID=40567911

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104534A AR068910A1 (es) 2007-10-19 2008-10-17 Preparacion farmaceutica solida de tipo matriz que comprende un polimero enterico

Country Status (24)

Country Link
US (2) US9072670B2 (es)
EP (1) EP2180882B2 (es)
JP (1) JP4879351B2 (es)
KR (2) KR20150064227A (es)
CN (1) CN101854920B (es)
AR (1) AR068910A1 (es)
AU (1) AU2008313032B2 (es)
BR (1) BRPI0817822A2 (es)
CA (1) CA2702904A1 (es)
CY (1) CY1114051T1 (es)
DK (1) DK2180882T3 (es)
ES (1) ES2406939T3 (es)
HK (1) HK1144775A1 (es)
HR (1) HRP20130498T1 (es)
IL (1) IL204706A (es)
MX (1) MX2010004178A (es)
MY (1) MY147827A (es)
PL (1) PL2180882T3 (es)
PT (1) PT2180882E (es)
RU (2) RU2465916C2 (es)
SI (1) SI2180882T1 (es)
TW (1) TWI433679B (es)
WO (1) WO2009051022A2 (es)
ZA (1) ZA201002211B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2619547C (en) 2007-02-06 2016-05-17 Smith International, Inc. Polycrystalline diamond constructions having improved thermal stability
US7942219B2 (en) 2007-03-21 2011-05-17 Smith International, Inc. Polycrystalline diamond constructions having improved thermal stability
US9297211B2 (en) 2007-12-17 2016-03-29 Smith International, Inc. Polycrystalline diamond construction with controlled gradient metal content
AR071706A1 (es) * 2008-05-15 2010-07-07 Otsuka Pharma Co Ltd Una formulacion farmaceutica de cilostazol solida de liberacion sostenida y metodo de preparacion.
WO2010009430A2 (en) 2008-07-17 2010-01-21 Smith International, Inc. Methods of forming thermally stable polycrystalline diamond cutters
CN102020609A (zh) * 2009-09-17 2011-04-20 北京本草天源药物研究院 托伐普坦晶体或无定形物及其制备方法
CN102293734A (zh) * 2010-06-25 2011-12-28 江苏恒瑞医药股份有限公司 托伐普坦固体分散体及其制备方法
CN102552278A (zh) * 2010-12-23 2012-07-11 天津泰普药品科技发展有限公司 一种提高难溶性药物托伐普坦溶出度的药物组合物
CN102558051B (zh) * 2011-07-15 2016-08-10 天津泰普药品科技发展有限公司 一种托伐普坦晶体及其药物组合物
CN103007286B (zh) * 2011-09-28 2016-06-15 北京本草天源药物研究院 一种托伐普坦的固体药物组合物
TWI615157B (zh) * 2013-02-06 2018-02-21 大塚製藥股份有限公司 包括不定形西洛他唑的固體分散劑
TWI660748B (zh) * 2013-03-01 2019-06-01 日商大塚製藥股份有限公司 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液
CN103880747B (zh) * 2014-03-20 2015-08-26 成都百裕科技制药有限公司 无定形托伐普坦的制备方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN106511351B (zh) * 2016-12-27 2020-04-03 吉林省博大伟业制药有限公司 聚普瑞锌在制备抗幽门螺旋杆菌药物中的应用
CN108478581A (zh) * 2018-05-09 2018-09-04 南通大学 防治运动病、梅尼埃病的药物及托伐普坦的医药用途
KR102138253B1 (ko) * 2018-08-17 2020-07-29 한국유나이티드제약 주식회사 실로스타졸 서방성 제제
WO2022150535A1 (en) * 2021-01-08 2022-07-14 Board Of Trustees Of Michigan State University Methods for forming cellulosic-based containers, related articles, and related compositions

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US202090A (en) * 1878-04-09 Improvement in plows
US3491070A (en) * 1966-11-25 1970-01-20 Goodrich Co B F 2 - ethylhexyl acrylate - n - octyl acrylamide - methacrylamide / acrylamide terpolymer
JPS6051106A (ja) 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤
US4968508A (en) 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US5209933A (en) † 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
JPH0443049A (ja) 1990-06-08 1992-02-13 Ricoh Co Ltd サーマルヘッドと厚膜金電極へのメッキ方法
SE9100284D0 (sv) † 1991-01-30 1991-01-30 Astra Ab Novel peptide
JPH0624991A (ja) 1991-06-20 1994-02-01 Tokyo Tanabe Co Ltd ウルソデスオキシコール酸持続性製剤
JPH06199657A (ja) 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
JPH115739A (ja) * 1997-06-17 1999-01-12 Taisho Yakuhin Kogyo Kk ベザフィブラート含有持続性製剤およびその製造方法
AU9182498A (en) * 1997-10-03 1999-04-27 Elan Corporation, Plc Taste masked formulations
WO1999052528A1 (en) 1998-04-11 1999-10-21 Errekappa Euroterapici S.P.A. Pharmaceutical preparations containing hydrosoluble ketoprofen salts and their application
CN1272785A (zh) † 1998-06-11 2000-11-08 Em工业股份有限公司 微渗透药物控释系统
FR2781152B1 (fr) † 1998-07-20 2001-07-06 Permatec Tech Ag Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation
GT199900148A (es) * 1998-09-10 2001-02-28 Desnaturalizantes para las sales aminas simpaticomimeticas.
IN191239B (es) * 1999-06-11 2003-10-11 Ranbaxy Lab Ltd
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
DE10046541A1 (de) * 2000-09-19 2002-03-28 Knoll Ag Mechanisch stabile darreichungsformen, enthaltend Ubichinone
WO2002102414A1 (en) * 2001-06-14 2002-12-27 Otsuka Pharmaceutical Co., Ltd. Medicinal compositions
EP1413294B1 (en) 2001-07-27 2010-09-29 Astellas Pharma Inc. Composition comprising sustained-release fine particles for quick-disintegrating tablets in the buccal cavity
CN100408029C (zh) † 2001-09-28 2008-08-06 麦克内尔-Ppc股份有限公司 有镶嵌部分的组合剂型
AU2003206382B2 (en) 2002-01-03 2008-01-24 Smithkline Beecham Corporation Novel pharmaceutical dosage forms and method for producing same
US7790215B2 (en) 2002-03-26 2010-09-07 Purdue Pharma Lp Sustained-release gel coated compositions
US6946156B2 (en) † 2002-05-15 2005-09-20 Mcneil-Ppc, Inc. Process for enrobing a core
RU2356549C2 (ru) * 2002-12-17 2009-05-27 Эббетт ГмбХ унд Ко.КГ Композиция, включающая фенофибриновую кислоту, ее физиологически приемлемую соль или производное
TWI357815B (en) 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
US20050147663A1 (en) † 2003-07-17 2005-07-07 Mohan Mailatur S. Method of treatment for improved bioavailability
JP2005206490A (ja) * 2004-01-21 2005-08-04 Pola Chem Ind Inc 経口投与用の組成物
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
US20050196355A1 (en) * 2004-03-03 2005-09-08 Constantine Georgiades Film products having controlled disintegration properties
US20050196447A1 (en) † 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
GB2418854B (en) * 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
CA2589493A1 (en) † 2004-12-17 2006-06-22 Boehringer Ingelheim International Gmbh Combination therapy comprising telmisartan and hydrochlorothiazide
US20060159753A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
MX2008000084A (es) * 2005-06-29 2008-03-18 Panacea Biotec Ltd Composiciones farmaceuticas de liberacion sostenida y procedimientos de las mismas.
EP1968553A2 (en) 2005-11-09 2008-09-17 Novartis AG Process for making pharmaceutical compositions with a transient plasticizer
SG2014009252A (en) 2005-12-22 2014-05-29 Otsuka Pharma Co Ltd Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol
WO2007085024A2 (en) 2006-01-21 2007-07-26 Abbott Gmbh & Co. Kg Dosage form and method for the delivery of drugs of abuse
EP1978944B1 (en) * 2006-01-24 2012-08-15 R-Tech Ueno, Ltd. Soft-gelatin capsule formulation

Also Published As

Publication number Publication date
JP4879351B2 (ja) 2012-02-22
IL204706A0 (en) 2010-11-30
MX2010004178A (es) 2010-05-03
PL2180882T3 (pl) 2013-08-30
HRP20130498T1 (en) 2013-06-30
JP2011500511A (ja) 2011-01-06
AU2008313032B2 (en) 2013-05-02
TWI433679B (zh) 2014-04-11
EP2180882A2 (en) 2010-05-05
US20100233265A1 (en) 2010-09-16
WO2009051022A2 (en) 2009-04-23
CA2702904A1 (en) 2009-04-23
RU2012132627A (ru) 2014-02-10
CY1114051T1 (el) 2016-07-27
EP2180882B2 (en) 2017-06-28
HK1144775A1 (en) 2011-03-11
RU2600797C2 (ru) 2016-10-27
KR101600099B1 (ko) 2016-03-04
RU2465916C2 (ru) 2012-11-10
DK2180882T3 (da) 2013-05-27
ZA201002211B (en) 2011-06-29
CN101854920B (zh) 2013-05-01
AU2008313032A1 (en) 2009-04-23
TW200918079A (en) 2009-05-01
KR20100087011A (ko) 2010-08-02
BRPI0817822A2 (pt) 2015-03-31
WO2009051022A3 (en) 2009-06-25
CN101854920A (zh) 2010-10-06
PT2180882E (pt) 2013-05-07
KR20150064227A (ko) 2015-06-10
IL204706A (en) 2014-05-28
RU2010119926A (ru) 2011-11-27
US9289389B2 (en) 2016-03-22
MY147827A (en) 2013-01-31
SI2180882T1 (sl) 2013-05-31
ES2406939T3 (es) 2013-06-10
EP2180882B1 (en) 2013-03-27
US9072670B2 (en) 2015-07-07
US20150150806A1 (en) 2015-06-04

Similar Documents

Publication Publication Date Title
AR068910A1 (es) Preparacion farmaceutica solida de tipo matriz que comprende un polimero enterico
ES2613308T3 (es) Composiciones para el tratamiento de la enfermedad del reflujo gastroesofágico (ERGE)
ES2496892T3 (es) Formulaciones para el tratamiento de trastornos del tracto respiratorio superior
CL2009002073A1 (es) Composicion farmaceutica solida para la liberacion controlada de un agente activo activo en el tracto gastrointestinal que comprende al menos un agente acido con solubilidad de menos de 0,3 mg/ml en solucion acuosa a un ph alrededor del pka del agente acido, un polimero hidrofilo, un alcanizador; uso en trastornos cardiovasculares.
CL2011002968A1 (es) Forma de dosificacion de extrusion por fusion caliente de un ingrediente activo (a) incluido en una matriz que comprende un polimero (c), que el nucleo presenta una orientacion morfologica ortogonal respecto a la direccion longitudinal de extension de la forma de dosificacion; y su procedimiento de preparacion.
ES2523959T3 (es) Conector de dispositivo medico
AR088381A1 (es) Formulaciones de etanercept estabilizadas con meglumina
DK1719503T3 (da) Anvendelse af stivelse med fraspaltede sidekæder i ekstrudering/sfæronisering af farmaceutiske pellets
CO6321225A2 (es) Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico
AR049732A1 (es) Proceso para enriquecer una poblacion de celulas de esperma
ITMI20061672A1 (it) Formulazioni di acido acetilsalicilico o suoi derivati in capsule molli,esibenti elevata stabilita'
EA200901365A1 (ru) Стабилизированная фармацевтическая композиция, содержащая прегабалин
AR059357A1 (es) Formulaciones farmaceuticas
ES2527006T3 (es) Envase blíster múltiple para pilas de botón
AR070180A1 (es) Sistema interconectado para enfriar el suministro de aire a un edificio
AR057178A1 (es) Formulaciones liquidas que contienen dialquil-sulfosuccinatos e inhibidores de la hidroxifenilpiruvato -dioxigenasa
AR072671A1 (es) Metodos y composiciones para el mejoramiento de las plantas
ES2577150T3 (es) Preparación farmacéutica que contiene selenita o compuestos que contienen selenita para el tratamiento de displasias o carcinomas cervicales
ECSP109871A (es) Soluciones farmacéuticas orales que contienen telbivudina
AR060869A1 (es) Composicion farmaceutica solida de gabapentina
EA200800150A1 (ru) Состав с пролонгированным высвобождением действующих начал лекарственного средства
TH104494B (th) สารเตรียมของแข็งทางเภสัชกรรม
TH124834A (th) องค์ประกอบทางเภสัชกรรมซึ่งให้ทางปากที่เกิดไมโครอิมัลชันได้เองของยาที่ชอบน้ำและวิธีการเตรียมของมัน
RU2013133363A (ru) Способ профилактики повреждения биологических мембран
RU2007132926A (ru) Противотуберкулезное средство в виде раствора для инъекций

Legal Events

Date Code Title Description
FB Suspension of granting procedure